USPTO Approved the Patent Application for OBI-888 “Antibodies, pharmaceutical compositions and uses thereof”
Date of occurrence: October 6, 2017 Company name: OBI Pharma Inc. Relationship to the Company (please enter ”head office” or ”affiliated company”): head office Reciprocal shareholding ratios: N/A Cause of …
Contract Signing with Pharmacore for the Contract Manufacturing of OBI-858
Date of occurrence: September 25, 2017 Contract or the other party to the contract: PharmaCore Biotech Co., Ltd Relationship to the Company (please enter ”head office” or ”affiliated company”): None …
Announcement on Change of the Acting Spokesperson
Type of personnel changed (please enter: spokesperson, acting spokesperson, important personnel(CEO, COO, CMO, CSO, etc.),financial officer, accounting officer, research and development officer, or internal audit officer): acting spokesperson Date of …
Announcement on Change of the Head of Finance and Accounting
Type of personnel changed (please enter: spokesperson, acting spokesperson, important personnel(CEO, COO, CMO, CSO, etc.),financial officer, accounting officer, research and development officer, or internal audit officer): Officer, Financial and Accounting …
OBI Received a Civil Complaint from Taiwan Shilin District Court
Parties to the legal matter: Plaintiff: Securities and Futures Investors Protection Center (SFIPC) Defendant: OBI Pharma, Inc. and Dr. Michael N. Chang (Chairman) Name of the legal agency or court: …
Clarification on the news article by China Times
Date of occurrence: July 12, 2017 Company name: OBI Pharma, Inc. Relationship to the Company (please enter ”head office” or ”affiliated company”): N/A Reciprocal shareholding ratios: N/A Name of mass …
Licensing agreement of ThioBridge™ signed with Abzena (AIM: ABZA)
OBI Pharma (‘OBI’, TPEx: 4174) has signed a licensing agreement and a master services and clinical supply agreement with Abzena plc (AIM: ABZA, ‘Abzena’ or the ‘Group), a UK-based life …
Clarification on the news article by Commercial Times
Date of occurrence: June 29, 2017 Company name: OBI Pharma, Inc. Relationship to the Company (please enter ”head office” or ”affiliated company”): N/A Reciprocal shareholding ratios: N/A Name of mass …
Important Resolutions of AGM 2017
Date of the meeting: June 28, 2017 Resolution #1: The 2016 earning distribution and expense appropriation was recognized. Resolution #2: Amended items—None Resolution #3: The 2016 Annual report and financial …
Supplemental information on the approved application of Phase III clinical trial of OBI-822, the novel breast cancer drug, in China, US, and the EU
Date of occurrence: June 11, 2017 Company name: OBI Pharma, Inc. Relationship to the Company (please enter ”head office” or ”affiliated company”): N/A Reciprocal shareholding ratios: N/A Name of mass …